
    
      Phase I/II, multicentre, open label, with no control arm clinical trial of 4-weeks
      stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks in adults with
      locally advanced pancreatic cancer who does not progress during 4 cycles of standard
      chemotherapy FOLFIRINOX
    
  